Targeting the Hypoxic Tumor Microenvironment
Stephen Cary, Ph.D., Co-Founder & CEO, Omniox
What Will the IMPACT of the Microbiome be on Cancer Immunotherapy?
Vancheswaran Gopalakrishnan, Ph.D., Post-Doctoral Fellow, Surgical Oncology, University of Texas MD Anderson Cancer Center
Jennifer Wargo, M.D., M.M.Sc., Associate Professor, Surgical Oncology, University of Texas MD Anderson Cancer Center
Parker Institute for Cancer Immunotherapy - Tumor Neoantigen Selection Alliance (TESLA)
Danny Wells, Ph.D., Scientist, Informatics, Parker Institute for Cancer Immunotherapy
Download 2017 Brochure